
Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target
Vanda Pharmaceuticals (VNDA) Analyst Ratings
Bulls say
Vanda Pharmaceuticals Inc. is positioned for significant revenue growth due to its diverse product portfolio and the potential of its compounds, particularly tradipitant, which is now linked to the prevention of nausea and vomiting in patients using GLP-1 receptor agonists. The company’s prospects are further enhanced by the expected long-term market exclusivity for milsaperidone, with exclusivity extending to 2044, which supports robust future revenue streams from approved indications. Additionally, positive clinical trial results for tradipitant may lead to increased demand and enhanced compliance for therapies that address critical health issues, reflecting the company's strong foundation for innovation and patient benefits.
Bears say
Vanda Pharmaceuticals faces significant risks that negatively affect its financial outlook, primarily due to slower-than-expected sales traction for key products like Fanapt and Ponvory, along with accelerated generic erosion impacting Fanapt and Hetlioz. Additionally, adverse pricing developments, particularly concerning Medicare reimbursement, and potential regulatory setbacks for late-stage pipeline candidates pose further threats to revenue stability. The company also grapples with medium- to long-term dilution risks and uncertainty surrounding operational changes, including potential M&A activities that could destabilize its shareholder base.
This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Vanda Pharmaceuticals (VNDA) Analyst Forecast & Price Prediction
Start investing in Vanda Pharmaceuticals (VNDA)
Order type
Buy in
Order amount
Est. shares
0 shares